Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report)’s stock price was down 5.3% during trading on Wednesday . The company traded as low as $13.03 and last traded at $13.05. Approximately 201,325 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 928,043 shares. The stock had previously […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) – Equities researchers at HC Wainwright lifted their Q3 2023 earnings per share estimates for shares of Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, August 8th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of […]
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01), Yahoo Finance reports. Day One Biopharmaceuticals Price Performance Shares of DAWN stock opened at $13.07 on Wednesday. The firm has a fifty day moving […]
Wedbush reaffirmed their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) in a research report report published on Tuesday morning, RTT News reports. They currently have a $38.00 target price on the stock. A number of other equities research analysts have also recently issued reports on DAWN. Needham & Company LLC […]